Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?

dc.creatorVillar, Livia M.
dc.creatorMelo, Maria M. M. de
dc.creatorCalado, Izabelle A.
dc.creatorAlmeida, Adilson J. de
dc.creatorLampe, Elisabeth
dc.creatorGaspar, Ana M. C.
dc.date2018-12-26T13:48:40Z
dc.date2018-12-26T13:48:40Z
dc.date2009
dc.date.accessioned2023-09-27T00:05:34Z
dc.date.available2023-09-27T00:05:34Z
dc.identifierVILLAR, Livia M. et al. Should Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?. Hepatology, v.24,p.238-242, 2009.
dc.identifier0270-9139
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30773
dc.identifier10.1111/j.1440-1746.2008.05575.x
dc.identifier1527-3350
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8897346
dc.descriptionHepatitis A virus (HAV) superinfection is associated with a high risk of liver failure and death in patients with hepatitis C virus (HCV) infection. The aim of this study was to investigate the presence of serological and molecular HAV markers in a population of HCV-infected patients in order to determine a cost-effective strategy to vaccinate against HAV.
dc.description2030-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsrestricted access
dc.subjectVìrus da Hepatite A
dc.subjectVírus da Hepatite C
dc.subjectVacinação
dc.subjecthepatitis A virus
dc.subjecthepatitis C virus
dc.subjectVaccination
dc.titleShould Brazilian patients with chronic hepatitis C virus infection be vaccinated against hepatitis A virus?
dc.typeArticle


Este ítem pertenece a la siguiente institución